AI assistant
Sending…
Hansa Biopharma — Major Shareholding Notification 2021
Apr 8, 2021
3057_iss_2021-04-08_10e40d31-34d7-4101-932d-d8edc056b073.pdf
Major Shareholding Notification
Open in viewerOpens in your device viewer
Issuer Hansa Biopharma AB
Holder
Handelsbanken Fonder AB
Instrument
| Instrument | Aktie SE0002148817 | ||||
|---|---|---|---|---|---|
| Before the transaction | |||||
| Shares | 2,232,823 | ||||
| Voting rights | 2,232,823 | ||||
| Transaction | |||||
| Date | 07/04/2021 |
| Limit for number of shares 5 % | ||||
|---|---|---|---|---|
After the transaction
Quantity Shares 2,332,823 Directly held voting rights 2,332,823 Indirectly held voting rights 0
Percentage
Directly held shares 5.08 % Directly held voting rights 5.23 % Indirectly held voting rights 0 %
Resulting distribution of total holdings
| Percentage of voting rights: |
Number of underlying shares: |
|
|---|---|---|
| Shares | 5.23 % | 2,332,823 |
| Instruments - FITA Ch. 4, section 2, first paragraph, line 2 Instruments - FITA Ch. 4, section 2, first paragraph, line 3 |
||
| - Physically settled - Cash settled |
||
| Total | 5.23 % | 2,332,823 |
| Group total holdings | ||
| Voting rights Percentage of voting rights 5.23 |
2,332,823 | |
| Published 08/04/2021 14:05 |
||
| Contact Name Maria Forssman Phone 08-7011763 |
Email [email protected] | |
CLOSE PRINT
[email protected] Tfn 08-408 980 37 Fax 08-24 39 25
More from Hansa Biopharma
Regulatory Filings
2026
May 19
Regulatory Filings
2026
May 19
Proxy Solicitation & Information Statement
2026
Apr 28
Proxy Solicitation & Information Statement
2026
Apr 28
Interim / Quarterly Report
2026
Apr 23
Interim / Quarterly Report
2026
Apr 23
Annual Report
2026
Mar 26
Annual Report
2026
Mar 26
Capital/Financing Update
2026
Mar 20
Capital/Financing Update
2026
Mar 20